https://www.tipranks.com/news/the-fly/veeva-price-target-raised-to-245-from-240-at-scotiabank Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price ...
Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...
Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP ...
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback